Asthma Clinical Trial
Official title:
Histoblood Group Antigens, Viruses and Asthma
This study will evaluate the link between blood group antigens and asthma exacerbations.
BACKGROUND:
The purpose of this study is to explore the role of histoblood group antigens in
virus-induced asthma exacerbations. These antigens (ABH and Lewis) decorate O- and N-linked
glycans on mucin and epithelial glycoproteins, respectively. Glycan synthesis involves
glycosyltransferases, including fucosyltransferases (FUT) encoded by FUT genes. Glycan
degradation involves glycosidases, including fucosidase. "Secretor status" is defined by
FUT2 activity in epithelial cells, which forms the H antigen and allows subsequent synthesis
and secretion of A, B, and Lewis B antigens. In preliminary studies it was found that: 1)
asthmatic patients with frequent exacerbations are more likely than non-exacerbated patients
to be secretors; 2) secretors report more frequently that a cold causes asthma; and 3)
sputum in stable asthma has abnormally high fucosidase activity. These findings suggest that
airway glycans are subjected to the following two competing homoeostatic influences: 1) the
diversity and activity of glycosyltransferases within cells that synthesize glycans; and 2)
the diversity and activity of glycosidases that turn over and remodel glycans in the airway
lumen. This study will test the hypothesis that secretor positive asthmatic patients are
susceptible to virus-induced asthma exacerbation and that abnormal glycosidase activity in
secretions modifies the glycan coat and promotes virus-induced exacerbation.
DESIGN NARRATIVE:
Secretor status will be studied in order to determine whether it is a risk factor for asthma
exacerbations precipitated by viruses. Preliminary studies suggest that secretor positive
asthmatics are prone to asthma exacerbations and that asthmatic patients have abnormal
glycosidase activity in their airway secretions. This study will explore these findings
further in the following two ways: 1) a case-control study will compare secretor status and
frequency of viral airway infection in 50 asthmatic patients hospitalized for management of
acute severe asthma to 50 asthmatic subjects in the outpatient setting without a history of
severe asthma exacerbation. Sputum samples or tracheal aspirates (from intubated patients)
will be collected from all patients. In these samples, DNA will be used as a microarray to
detect viruses; and 2) epithelial brushings and bronchial biopsies from a tissue bank will
be used to establish the relationship between secretor status (erythrocyte Lea and Leb
phenotyping) and airway epithelial cell activity of FUT genes (real time RT-PCR), and
expression of Lea, Leb, A, B, and H antigens (immunohistochemistry).
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|